
(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
How to watch ‘The Traitors’ Season 4: Premiere date, episode release time, full cast list and more - 2
Medicine doesn’t just have ‘conscientious objectors’ − there are ‘conscientious providers,’ too - 3
Criminal Guard Lawyer Expenses: What Would it be advisable for you to Hope to Pay? - 4
Releasing Learning Experiences: A Survey of the \Learning Made Fun\ Instructive Application - 5
General Atlantic says ‘biggest mistake’ would be pulling back on Gulf deals
Ageless Tastefulness: An Outline of Valuable Gemstones and Adornments
Enormous Credit And All that You Really want To Be aware
Several Israelis attempt to cross into Gaza, escorted back to Israel by IDF
7 Fast Approaches to Let loose Space on Your Telephone in a flash
Conquering Language Boundaries: Individual Accounts of Multilingualism
In Antarctica, photos show a remote area teeming with life amid growing risks from climate change
Fossils from China show complex life evolved millions of years earlier than once thought
Vote In favor of Your Favored Shades
Central African Republic's president sworn in for a third term after disputed election













